Mydecine Innovations Group (TSE:MYCO) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mydecine Innovations Group, a biotech firm focused on developing treatments for mental health disorders, has had its shares suspended from trading on the Aquis Growth Market due to non-payment of exchange fees. The company, which is pioneering next-generation medications including psychedelic compounds for conditions like PTSD and nicotine addiction, made the announcement and acknowledged its responsibility.
For further insights into TSE:MYCO stock, check out TipRanks’ Stock Analysis page.